Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Open accessThe DOI matches its Crossref record; 242 of the 246 references it cites were found in a registry or an index.
Abstract
Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere with mechanisms of angiogenesis related to tumor microenvironment might represent a promising strategy. In this review, we deepened research on the molecular mechanisms underlying anti-angiogenic strategies and their failure and went further into the alternative mechanisms that impact angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tyrosine kinase inhibitors (TKIs) have broadened the scope of anti-angiogenic therapy to include other pro-angiogenic growth factors and receptors such as PDGFR, FGFR, c-MET, and PIGF, which are now mainstay targets of the targeted therapy arsenal (Table 2) [33].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Park, S. Y., Kang, J. H., Jeong, K. J., Lee, J., Han, J. W., Choi, W. S., Kim, Y. K., Kang, J., Park, C. G., & Lee, H. Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.25589 · Cited by 135
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“The blockage of the VEGF:VEGFR axis seems to be ineffective as monotherapy, and primary or de novo resistance is a common feature in cancer patients [23,123].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“These strategies have focused mainly on eye disease [110] and wound healing [111], but their application in cancer therapy is under debate [112,113].”
BackgroundAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · cited 1×
“on tumor growth and an increase in OS [161].”
BackgroundVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 1×
“Moreover, the design and development of new anti-VEGF signaling drugs continues, including the arylamide-5-anilinoquinazoline-8nitro derivative a recent inhibitor of VEGFR2-kinase activity with in vitro anti-tumor and anti-angiogenic activity [38].”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Research works printed but not linked: 1
- 5. Domingues, G.; Fernandes, S.G.; Serpa, J. Dynamics of VEGF-A and its Receptors in Cancer Vascularization-An Overview. In Understand Cancer: Research and Treatment ; iConcept Press: Hong Kong, China, Chapter 3; 2015; ISBN 978-1-922227-386.
Cited by
Items 101–200 of 428
Peña-Flores, J. A., Muela‐Campos, D., Guzmán-Medrano, R., Enríquez-Espinoza, D., & González-Alvarado, K. (2024) · Non-Coding RNA · doi:10.3390/ncrna10010012 · Cited by 18
“Multiple efforts have been made to develop antiangiogenic therapies to halt tumor growth and prevent metastasis [8,9].”
BackgroundMoving beyond traditional therapies: the role of nanomedicines in lung cancer
Zhang, J., Li, Y., Guo, S., Zhang, W., Fang, B., & Wang, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1363346 · Cited by 26
Jiménez, D. J., Javed, A., Rubio‐Tomás, T., Seye-Loum, N., & Barceló, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052860 · Cited by 16
“While this strategy has extended the lives of many patients, emerging clinical studies suggest that anti-angiogenic therapy may unintendedly promote more invasive tumors and increase the risk of metastasis to distant organs [128,129].”
BackgroundCorreia, M. J., Pimpão, A. B., Lopes‐Coelho, F., Sequeira, C. O., Coelho, N. R., Dias, C. G., Barouki, R., Coumoul, X., Serpa, J., Morelló, J., et al. (2021) · Antioxidants · doi:10.3390/antiox10091484 · Cited by 14
“Both processes are pivotal for the prevention of vascular remodeling [79].”
BackgroundSelf-citationProgress in the treatment of malignant ascites
Wang, Y., Sun, Y., Li, X., Yu, X., Zhang, K., Liu, J., Tian, Q., Zhang, H., Du, X., & Wang, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104237 · Cited by 18
Lenvatinib enhances antitumor immunity of anti-PD-1 antibody
Kato, Y. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02721-5 · Cited by 13
Mendoza‐Torreblanca, J. G., Cárdenas‐Rodríguez, N., Carro-Rodríguez, J., Contreras‐García, I. J., Garciadiego-Cázares, D., Ortega-Cuéllar, D., Martínez-López, V., Alfaro-Rodríguez, A., Evia-Ramírez, A. N., Ignacio‐Mejía, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210199 · Cited by 15
“Although the antiangiogenic mechanism mediated by the VEGF/VEGFR 2 pathway is one of the most important mechanisms [5,6], we should not omit that alternative proangiogenic pathways could be activated [6], especially in cancer and possibly in endometriosis and OA as an adaptive response.”
BackgroundMerino, J. J., Durán, A. G., Chinchilla, N., & Macías, F. A. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10089-7 · Cited by 18
“Antiangiogenic therapies have attracted special interest because they involve inhibiting angiogenesis to deprive tumors of the necessary nutrients and oxygen for growth and metastasis (Lopes-Coelho et al. 2021).”
Angiogenesis causes and vasculogenic mimicry formation in the context of cancer stem cells
Li, Y., Liu, X., Dong, Y., & Zhou, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189323 · Cited by 17
Suprabasin: Role in human cancers and other diseases
Tan, H., Wang, L., & Liu, Z. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06897-7 · Cited by 14
Feng, Y., Tang, L. M., Wang, H., Liu, Y., Yang, S., Lin, L., Hu, X., & Shi, Y. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03251-z · Cited by 13
Wang, H., Wu, Z., Fan, X., Wu, C., Lu, S., Geng, L., Stalin, A., Zhu, Y., Zhang, F., Huang, J., et al. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00710-2 · Cited by 15
“VEGFA is expressed in almost all types of malignant tumors and is currently still an important target for antiangiogenesis drugs targeting tumors [32].”
BackgroundHu, Y., Yue, G. G., Li, X., Xu, G., & Lau, C. B. (2023) · Phytochemistry · doi:10.1016/j.phytochem.2023.113727 · Cited by 13
Dashtaki, M. E., & Ghasemi, S. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467216666221206100135 · Cited by 17
Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer
Xu, D., Luo, Y., Wang, P., Li, J., Ma, L.-R., Huang, J., Zhang, H., Yang, X., Li, L., Zheng, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1148131 · Cited by 16
Greifová, H., Tokárová, K., Jambor, T., Knížatová, N., Speváková, I., Dupák, R., Balytska, O., Bažány, D., Capcarová, M., & Lukáč, N. (2023) · Life · doi:10.3390/life13091921 · Cited by 12
“In this context, IL-8 production is an important marker for tracking carcinogenesis, because angiogenesis plays a key role in the growth of tumors and metastasis; therefore, it represents a promising target for cancer therapy [11].”
BackgroundEffects of propranolol on glucose metabolism in hemangioma-derived endothelial cells
Yang, K., Li, X., Qiu, T., Zhou, J., Gong, X., Lan, Y., & Ji, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115922 · Cited by 14
Li, N., Yu, Y., Chen, Q., Niu, J., Gao, C., Qu, X., Zhang, J., & Gao, H. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.05.051 · Cited by 12
Hassan, H. M., Hassan, R., Elmagzoub, R. M., Al‐Emam, A., Kossenas, K., Abdel-Samea, A. S., Khalifa, H. O., Akocak, S., Braese, S., & Hashem, H. (2025) · Pharmaceuticals · doi:10.3390/ph18010072 · Cited by 12
“Furthermore, exploring the safety and efficacy of these derivatives in combination with other drugs is essential to optimize therapeutic strategies.”
Application of nanoparticles to target tumor blood vessels as a promising cancer treatment strategy
Lorenc, P., Dams‐Kozlowska, H., Guzniczak, N., & Florczak, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118038 · Cited by 15
Angiogenesis goes computational – The future way forward to discover new angiogenic targets?
Subramanian, A., Zakeri, P., Mousa, M., Alnaqbi, H., Alshamsi, F. Y., Bettoni, L., Damiani, E., AlSafar, H. S., Saeys, Y., & Carmeliet, P. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.09.019 · Cited by 14
“…therapies focus on either blocking growth factor signaling pathways (e. g. vascular endothelial growth factor (VEGF) signaling), thereby blocking angiogenesis (anti-angiogenic therapy (AAT)), or delivering components, mostly growth factors, to promote angiogenesis (pro-angiogenic therapy) [2].”
BackgroundAngiogenesis unveiled: Insights into its role and mechanisms in cartilage injury
Wang, C., Gong, S., Liu, H., Cui, L., Ye, Y., Liu, D., Liu, T., Xie, S., & Li, S. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112537 · Cited by 11
“A key issue is the precise control of the extent and rate of vascularization to avoid either excessive or insufficient angiogenesis (Lopes-Coelho et al., 2021).”
BackgroundGuo, F., Li, H., Wang, J., Wang, J., Zhang, J., Kong, F., Zhang, Z., & Zong, J. (2024) · Cancer Management and Research · doi:10.2147/cmar.s477698 · Cited by 13
1,3,4‐Thiadiazole Derivatives as VEGFR‐2 Inhibitors and Its Molecular Insight for Cancer Therapy
Gawande, P., Matore, B. W., Murmu, A., Kumar, A., Jana, S., Roy, P. P., & Singh, J. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501361 · Cited by 14
“Monoclonal antibodies like bevacizumab and small molecule inhibitors such as sunitinib are among the agents used in anti-angiogenic therapy [33–35].”
Matteo, A. D., Belloni, E., Pradella, D., Chiaravalli, A. M., Pini, G. M., Bugatti, M., Alfieri, R. R., Barzan, C., Tena, E. F., Bione, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098102 · Cited by 11
“treatments have been developed to block oxygen and nutrient supply to tumor cells, thus inducing cancer regression [2].”
BackgroundImplant presence-triggered osteonecrosis: A scoping review
Yong, C. W., Sng, T. J. H., Choo, S. H. J., Chew, R. J. J., & Islam, I. (2024) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2024.101759 · Cited by 10
Immunotherapy in gastric cancer—A systematic review
Santos, M. L. D., Martins, D. F., & Mendes, F. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.052207 · Cited by 12
“Additionally, the normalization of the abnormal vasculature within tumors improves drug delivery and enhances the ef fi cacy of other therapies, like chemotherapy [55].”
Dilek, Ö. (2025) · TURKISH JOURNAL OF CHEMISTRY · doi:10.55730/1300-0527.3741 · Cited by 11
“VEGFR2 is a promising target for antiangiogenic therapies with aim of inhibiting the growth of blood vessels in tumors to starve them of nutrients and oxygen [39].”
Wen, M., Shi, H., Wan, Y., Wu, J., Tian, X. B., Chen, Q., Wu, M., & Feng, S. (2023) · Chemical Communications · doi:10.1039/d3cc00088e · Cited by 10
Uhlik, M. T., Pointing, D., Iyer, S., Ausec, L., Štajdohar, M. R., Cvitkovič, R., Žganec, M., Culm, K., Santos, V. C., Pytowski, B., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1158345 · Cited by 10
Alfair, B. M., Jabarti, A. A., Albalawi, S. S., Khodir, A. E., & Al-Gayyar, M. M. H. (2023) · Cureus · doi:10.7759/cureus.44987 · Cited by 10
“VEGF also contributes to immunosuppression, which is linked to the Treg population and inversely related to the CD8+ cytotoxic T cell population [29].”
BackgroundMaximizing arsenic trioxide's anticancer potential: Targeted nanocarriers for solid tumor therapy
Yang, S., Raza, F., Li, K., Qiu, Y., Su, J., & Qiu, M. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114014 · Cited by 13
Combining Fruquintinib and Doxorubicin in Size-Converted Nano-Drug Carriers for Tumor Therapy
Zhang, N., Xin, X., Feng, N., Wu, D., Zhang, J., Yu, T., Jiang, Q., Gao, M. J., Yang, H. D., Zhao, S., et al. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01606 · Cited by 10
Mitochondrial UQCC3 controls embryonic and tumor angiogenesis by regulating VEGF expression
Zhang, G., Liu, B., Yang, Y., Xie, S., Chen, L., Luo, H. B., Zhong, J. Q., Wei, Y., Guo, F., Gan, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107370 · Cited by 9
“UQCC3 stabilizes HIF-1a under hypoxia and promotes angiogenesis In many mammalian species, angiogenesis occurs in a hypoxic environment.(29) Is UQCC3 levels also associated with hypoxia? We first examined the hypoxia using a hypoxia probe and measured UQCC3 levels in tumor tissues.”
BackgroundMethodUltrasound Localization Microscopy for Cancer Imaging
Porte, C., Dencks, S., Kohlen, M., Magnuska, Z., Lisson, T., Rix, A., Stickeler, E., Schmitz, G., & Kiessling, F. M. (2024) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2024.3508266 · Cited by 11
Keratibumrungpong, T., Srisuthtayanont, W., Wanachewin, O., Klangjorhor, J., Phitak, T., Pothacharoen, P., Shwe, T. H., & Kongtawelert, P. (2023) · Biomedicines · doi:10.3390/biomedicines11010188 · Cited by 10
“Angiopoietin 2 (Ang2), being the antagonist of Ang1 that stabilizes nascent vessels by recruiting mural cells, is implicated in the formation of unstable and leakier vessels and it is upregulated in many cancers [13].”
BackgroundSalem, G. E. M., Azzam, S. M., Nasser, M. A. F., Malah, T. E., Lateef, H. M. A. E., Khan, R. H., Chavanich, S. A., & Anwar, H. M. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124243 · Cited by 9
McCormick, A. L., Anderson, T. S., Daugherity, E. A., Okpalanwaka, I. F., Smith, S. L., Appiah, D., & Lowe, D. B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1241949 · Cited by 11
Montero‐Calle, A., de Ocaña, S. J., Benavente-Naranjo, R., Rejas‐González, R., Bartolomé, R. A., Martínez‐Useros, J., Sanz, R., Dziaková, J., Fernández‐Aceñero, M. J., Mendiola, M., et al. (2023) · Cells · doi:10.3390/cells12212548 · Cited by 9
“…target of intervention in blocking the angiogenic capacity of cancer cells, which might reduce their tumor growth and metastatic potential, with the aim of improving the prognosis and survival of CRC patients, as previously suggested for therapies based on antiangiogenic factors [62–64].”
BackgroundSurendran, V., Safarulla, S., Griffith, C. M., Ali, R., Madan, A., Polacheck, W. J., & Chandrasekaran, A. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c01766 · Cited by 9
Antiangiogenic Potential of Pomegranate Extracts
Tornese, R., Montefusco, A., Placì, R., Semeraro, T., Durante, M., Caroli, M. D., Calabrese, G., Caprifico, A. E., & Lenucci, M. S. (2024) · Plants · doi:10.3390/plants13233350 · Cited by 9
“Despite the theoretical promise of antiangiogenic strategies, their practical application has faced challenges [16].”
Decoding the Mechanism of Drugs of Heterocyclic Nature against Hepatocellular Carcinoma
Sugunan, S., Nath, L. R., Kumar, A. R., Anitha, L., Nair, B., & Mathew, B. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220418115310 · Cited by 9
Walsh, K. A., Kastrappis, G., Fifis, T., Paolini, R. A., Christophi, C., & Perini, M. V. (2022) · Cancers · doi:10.3390/cancers14112715 · Cited by 10
“The overall benefits, however, are limited and are often associated with unwanted side effects [6,7].”
BackgroundBarrette, L., Suresh, N. V., Salmon, M. K., Ravin, E. D., Harris, J., Kamdar, R. S., Moreira, A. G., & Rajasekaran, K. (2022) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2022.06.014 · Cited by 9
Nucleic Acid Delivery to the Vascular Endothelium
Reschke, M., Piotrowski-Daspit, A. S., Pober, J. S., & Saltzman, W. M. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00653 · Cited by 11
Wang, B., Yu, R.-Z., Zhang, X., Ren, Y., Zhen, Y., & Han, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217397 · Cited by 8
Sweeney, A., Langley, A., Xavierselvan, M., Shethia, R. T., Solomon, P., Arora, A., & Mallidi, S. (2025) · Theranostics · doi:10.7150/thno.99361 · Cited by 10
“The majority of antiangiogenic drugs target the vascular endothelial growth factor (VEGF) pathway, either by inhibiting VEGF-A with neutralizing antibodies or by blocking the VEGF-receptors (VEGFRs) with tyrosine kinase inhibitors (TKIs) [43-45].”
The interplay between angiogenesis and cervical cancer: a comprehensive review
Nandi, A., Ghosh, A., & Sil, S. K. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2501073 · Cited by 8
Interleukin‐24: A Multidimensional Therapeutic for Treatment of Human Diseases
Raguraman, R., Munshi, A., & Ramesh, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70013 · Cited by 8
“However, it is important to note that a singular approach of pharmacological inhibition of angiogenesis has not proven effective in curbing tumor growth and metastasis (Lopes-Coelho et al. 2021).”
Wen, L., Gan, M.-X., Xiong, S., Dai, L., Chen, W., & Shi, W. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101917 · Cited by 9
“Elevated VEGF levels correlate with disease progression and are critical targets for therapeutic intervention [4,7].”
Ali, E. A. M., Altaie, A. M., Talaat, I. M., & Hamoudi, R. (2025) · Cancers · doi:10.3390/cancers17172856 · Cited by 10
“[22] CXCL8/IL-8 (C-X-C motif chemokine ligand 8)/(Interleukin-8) Binds CXCR1/2 7 on endothelial cells, triggering PI3K/AKT 5 and MAPK/ERK 4 signaling.”
Attia, E. Z., Abdel-Rahman, I. A. M., Aly, O. M., Saber, H., Rushdi, M. I., & Abdelmohsen, U. R. (2023) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-023-00474-8 · Cited by 9
Reang, J., Sharma, V., Yadav, V., Tonk, R. K., Majeed, J., Sharma, A. K., & Sharma, P. C. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03252-w · Cited by 10
“Several studies have discovered that the expression of hypoxia-Table WO2008119771A2 [178] inducible factor-1 α (HIF-1 α ) escalates in reaction to therapy [144, 145].”
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
Gonzalez, N. S., Castet, F., Élez, E., Macarulla, T. M., & Tabernero, J. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021772 · Cited by 10
Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs
Hou, W., Zhong, J., Xiao, C., Cheng, Y., Zhao, C., Lin, Z., & Dan, C. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04560-7 · Cited by 8
“Clinically, axitinib, lenvatinib, pazopanib, apatinib, cabozantinib, regorafenib, and sorafenib have become approved drugs with acceptable therapeutic windows (Cohen and McGovern 2005; Ettrich and Seufferlein 2018; Hao and Wang 2020; Lopes-Coelho et al. 2021; Scott 2018), while semaxanib offers little benefit to patie…”
BackgroundAnti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
Tan, A. C., & Pavlakis, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168863 · Cited by 11
“This may include increased levels of other proangiogenic factors or activation of alternative VEGF-independent angiogenic pathways [44].”
BackgroundHe, Y., Zhai, A., Qin, K., Zhou, X., Yu, Y., & Zhang, Z. (2024) · Discover Oncology · doi:10.1007/s12672-024-01267-8 · Cited by 7
“While the precise mechanism remains elusive, resistance to anti-angiogenic therapy, a common challenge in cancer treatment, might contribute to this outcome according to existing literature [17].”
BackgroundAbdelall, E. K. A., Elshemy, H. A. H., Abdelmegeed, H., Ryad, N., & Abdelaziz, A. A. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109116 · Cited by 10
Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment
Wang, W., Mu, S., Zhang, J., Shan, G., Li, X., Wang, R., Guo, T., & He, X. (2026) · Advanced Science · doi:10.1002/advs.202519213 · Cited by 9
“In addition, the abnormal vascular structure and function the tumor less responsive to treatment, and chemotherapeutic drugs cannot be delivered to the tumor locally, resulting in greatly reduced efficacy [ 91 ].”
Aleman, J., Young, C. D., Karam, S. D., & Wang, X. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23417 · Cited by 10
“Patients positive for the C‐terminus of type VIII collagen were found to be potential candidates for antiangiogenesis therapy, a treatment that has yet to be successfully implemented.(185,186) It is conceivable”
BackgroundGenome Editing of Pik3cd Impedes Abnormal Retinal Angiogenesis
Wu, W., Ma, G., Qi, H., Dong, L., Chen, F., Wang, Y., Mao, X., Guo, X., Cui, J. Z., Matsubara, J. A., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.079 · Cited by 8
“10 In addition, anti-VEGF agents 9,11 such as aflibercept and ranibizumab, are being used to treat angiogenesis-related eye diseases.”
Bioactive compounds isolated from the bark of Aesculus glabra Willd
Cruz, M. V., Arellano, E. D. S., Castro, I., Jeyaraj, J. G., Ezzone, N. P. M., & de Blanco, E. J. C. (2024) · Phytochemistry Letters · doi:10.1016/j.phytol.2024.04.005 · Cited by 7
Sinensetin Inhibits Angiogenesis in Lung Adenocarcinoma via the miR-374c-5p/VEGF-A/VEGFR-2/AKT Axis
Ji, T., Lin, Y., Xi, E.-P., Liu, Y., Wang, X., & Wang, S. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01352-3 · Cited by 7
Zha, H., Li, F., Cai, L., Liu, W., Zhang, M., Gu, S., Feng, H., Xia, Z., Guo, C., Wu, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116889 · Cited by 9
Yousef, R. G., Eissa, I. H., Elkady, H., Mehany, A. B. M., Abo-Saif, M. A., Radwan, M. M., ElSohly, M. A., Ibrahim, I. M., Elwan, A., & El‐Zahabi, M. A. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2421150 · Cited by 7
Piccinno, E., Schirizzi, A., Scalavino, V., Leonardis, G. D., Donghia, R., Fantasia, A., Ricci, A. D., Lotesoriere, C., Giannelli, G., Serino, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413498 · Cited by 9
Choi, B.-K., Jo, M.-H., Shin, H. J., & Park, S. J. (2025) · Molecules · doi:10.3390/molecules30050987 · Cited by 7
“The specificity of LA for endothelial cells, along with its selective inhibition of VEGF/VEGFR2 signaling, distinguishes it from broad-spectrum anti-angiogenic agents that often cause off-target effects and toxicity [5,6,30].”
InfluentialZhu, H., Zhao, H., Peng, C. Y., Shu, H., Liu, Z., Zhou, Q., & Xiong, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115481 · Cited by 7
Lin, X., Li, H., Li, X., Yang, X., Shi, W., Ding, Z., Zhong, D., Li, Y., Yang, W., Yu, X., et al. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3140 · Cited by 7
Li, W., Lei, X., Li, Z., He, Y., Chen, M., Jiang, Z., & Chen, G. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108055 · Cited by 6
Molecular insights into the role of tumor-specific endothelial cells in metastasis
Taher, T. Z., Kheirkhah, A. H., Mehri, S., Mahmoudian, O., Atashi, S., & Kavianpour, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104964 · Cited by 8
Multilayered microfluidic platform for three-dimensional vascularized organ-on-a-chip applications
Zhou, C., Li, Z., Xu, J., Yu, D., Xuan, L., & Wang, X. (2025) · Bio-Design and Manufacturing · doi:10.1631/bdm.2500091 · Cited by 6
“Recent advances in antiangiogenic therapy have demonstrated that pharmacological inhibition of angiogenesis signaling pathways effectively suppresses tumor vascularization, ultimately limiting cancer progres‐ sion [3, 4].”
Sharma, B., Shekhar, H., Sahu, A., Haque, S., Kaur, D., Tuli, H. S., & Sharma, U. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10375-9 · Cited by 7
“An imbalance of various anti-angiogenic and pro-angiogenic factors is crucial for angiogenesis [35].”
Antagonizing the S1P-S1P3 Axis as a Promising Anti-Angiogenic Strategy
Avnet, S., Mizushima, E., Severino, B., Lipreri, M. V., Scognamiglio, A., Corvino, A., Baldini, N., & Cortini, M. (2025) · Metabolites · doi:10.3390/metabo15030178 · Cited by 6
“However, anti-VEGF monotherapies frequently yield limited durability due to resistance mechanisms and tumor adaptation [32].”
Anti-breast cancer potential of thieno-pyrimidine derivatives as VEGFR-2 inhibitors
Alsfouk, A. A., Ward, M. M. S. A., Al-Qadhi, M. A., El‐Metwally, S. A., Yousef, R. G., Elkaeed, E. B., Husein, D. Z., Amin, F. G., Elkady, H., Metwaly, A. M., et al. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2479422 · Cited by 7
Nanotherapeutic Formulations for the Delivery of Cancer Antiangiogenics
Ultimo, A., Jain, A., Gómez-González, E., Alex, T. S., Moreno-Borrallo, A., Jana, S., Ghosh, S., & Ruiz‐Hernández, E. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00822 · Cited by 8
Su, X.-Z., Qiao, E., Teng, G., & Xiong, F. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.07.055 · Cited by 6
Nerdy, N., Lestari, P., Fahdi, F., Putra, E., Amir, S., Yusuf, F., & Bakri, T. (2022) · Pharmacognosy Journal · doi:10.5530/pj.2022.14.13 · Cited by 8
Guan, X., Li, W., Wang, Y., Zhao, Q., Yu, X., Jiang, J., Bian, W., Xu, C., Sun, Y., & Zhang, C. (2023) · Toxicology Letters · doi:10.1016/j.toxlet.2023.01.012 · Cited by 6
Induced Vascular Normalization—Can One Force Tumors to Surrender to a Better Microenvironment?
Sun, X., Nosrati, Z., Ko, J., Lee, C.-M., Bennewith, K. L., & Bally, M. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082022 · Cited by 8
“and others changed this perspective, highlighting the concept of TVN [8,56].”
BackgroundPredicting a risk of tumor evolution considering regulatory mechanisms of the body and angiogenesis
Trusov, P. V., Зайцева, Н. В., & Chigvintsev, V. М. (2023) · Health Risk Analysis · doi:10.21668/health.risk/2023.4.13 · Cited by 6
Inflammation mediated angiogenesis in chronic lymphocytic leukemia
Ajtić, O. M., Živković, E., Subotički, T., Diklić, M., Đikić, D., Vukotić, M., Dragojević, T., Vuković, V., Antic, D. A., & Čokić, V. P. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05781-1 · Cited by 6
Irradiation immunity interactions
Davis, D. A. S., Atmosukarto, I. I., Garrett, J., Gosling, K. M., Syed, F. M., & Quah, B. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13399 · Cited by 6
Lessiak, U., Pratscher, B., Tichy, A., & Nell, B. (2023) · Veterinary Sciences · doi:10.3390/vetsci10110632 · Cited by 6
“The VEGF pathway is now targeted by almost all clinically approved anti-angiogenic drugs for addressing cancer and ocular diseases [1,10].”
BackgroundSun, X., Zhang, Z., Wang, Z., Xie, R., Yi, C., Liu, H., Chi, X., Li, T., Liu, H., Han, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1033967 · Cited by 6
Patel, V. K., Shirbhate, E., Singh, V. P., Parveen, S., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266324868250123052818 · Cited by 5
Beyond transcription: RNA-binding proteins steering angiogenesis
Hamm, K., Clifford, E. W., Kozak, K., Cullison, J., Iqbal, H., Yan, R., Xing, Y., & Liu, Z. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00465.2025 · Cited by 6
Polymersome-based nanomedicine for combined cancer therapy
Zonouz, A. M., Ebrahimpour, M., Zibaei, K., Ramezani, M., Taghavi, S., Abnous, K., Taghdisi, S. M., & Alibolandi, M. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2577137 · Cited by 7
Currenti, J., Mishra, A., Wallace, M., George, J., & Sharma, A. (2023) · PubMed Central · doi:10.1042/bst20220157 · Cited by 8
The Potential Role of the T2 Ribonucleases in TME-Based Cancer Therapy
Campomenosi, P., Mortara, L., Bassani, B., Valli, R., Porta, G., Bruno, A., & Acquati, F. (2023) · Biomedicines · doi:10.3390/biomedicines11082160 · Cited by 5
Carnosic Acid and its Pharmacological Activities: An Updated Review
Bhadouria, V. S., Kharbanda, J., Verma, S., Kumar, A., & Singh, S. K. (2024) · The Natural Products Journal · doi:10.2174/0122103155332776240909060924 · Cited by 7
Peña, M., Guzmán, A., Mesas, C., Porres, J. M., Martínez, R., Bermúdez, F., Melguizo, C., Cabeza, L., & Prados, J. C. (2024) · Nutrients · doi:10.3390/nu16234233 · Cited by 6
Wu, Y.-H., Sun, J., Huang, J., & Lu, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-83783-9 · Cited by 5
“In the field of modern medical therapies, especially for anti-angiogenic therapies, biomarker studies are of irreplaceable importance in the development of personalized treatment plans 18 .”
Tiwari, S. K., Chandrasekharan, A., Lupitha, S. S., Mathew, K. A., Jancy, S. V., Halikar, A. M., Sanjeev, V. S., Sivakumar, K. C., Prasad, T., Anurup, K. G., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.02.007 · Cited by 6
Nikolova-Mladenova, B., Mihaylova, R., Atanasova, M., Zhivkova, Z. D., & Doytchinova, I. A. (2025) · Molecules · doi:10.3390/molecules30051015 · Cited by 7
“Anti-angiogenic agents inhibit blood vessel formation [12], while hormone therapy drugs target receptors on cancer cells [13].”
Kim, H., El‐Khoury, V., Schulte, N., Zhan, T., Betge, J., Cousin, L., Felli, E., Pessaux, P., Ogier, A., Opitz, O. G., et al. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.2021042 · Cited by 5
“Apart from angiogenesis, other mechanisms account for tumor vascularization, in particular vessel cooption, a process whereby tumor cells incorporate and use preexisting vessels from the surrounding normal tissue to proliferate and spread, and vascular mimicry which is the acquisition by tumor cells of an endothelial-…”
BackgroundLugassy, C., Kleinman, H. K., Cassoux, N., & Barnhill, R. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.996411 · Cited by 7
Xian, F., Wu, J., Zhong, L., & Xu, G. (2023) · Medicine · doi:10.1097/md.0000000000033204 · Cited by 5
“The difference between HCC and others and the heterogeneity could be caused by the different sensitivity of tumors to the RIT-based regimens, which was consistent with published studies.[23,24] Moreover, the ORR of patients from the USA was better than that from China (85% vs 54%) by visual inspection, which may be du…”
ResultAdebayo-Gege, G. I., Ejembi, S. A., Umedum, N. L., Obidola, S. M., Ojo, O. A., Ika, M. D., Obialor, A., Johnson, G. I., Adegboyega, A. E., & Johnson, T. O. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101376 · Cited by 5
Guo, M., Li, S., Li, C., Mao, X., Tian, L., Yang, X., Xu, C., & Zeng, M. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09204-4 · Cited by 5
“…HGF hepatocyte growth factor, TGF-β1 transforming growth factor-beta1 array demonstrated that overexpression of Wnt5a upregulated the expression of protective factors, including pro-angiogenic factors VEGF [27] and Ang-1 [28], as well as anti-inflammatory factors FGF-10 [29] and HGF [30].”
Metadata
- Authors
- Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J.
- Affiliations
- Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
- Instituto Português de Oncologia Francisco Gentil (PT)
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Serpa, Jacinta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-05
- Volume
- 22
- Issue
- 7
- Pages
- 3765
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8038573
- OpenAlex
- W3140967360
- Cited by
- 416
- References
- 246
- Citations by year
- 2026: 61 · 2025: 98 · 2024: 117 · 2023: 86 · 2022: 46 · 2021: 8
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministério da Educação e Ciência
- Ministério da Ciência, Tecnologia e Ensino Superior
- Ministério da Educação
- Fundação para a Ciência e a Tecnologia (/2017, iNOVA4Health, PD/BD/128337/2017)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, angiogenesis, VEGF signaling, tumor microenvironment, cancer immunotherapy, immunosuppression, drug repurposing, combination therapy, tumor vasculature, treatment resistance
- MeSH terms
- Animals, Humans, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.